Company intelligence / Profile preview

Foamix Pharmaceuticals Ltd.

Ownership: Private
Employees: ~20
Development stage: Commercial

Overview

Foamix successfully developed AMZEEQ™ (minocycline) topical foam, 4%, which received FDA approval for the treatment of inflammatory lesions of non-nodular moderate-to-severe acne vulgaris in adults and pediatric patients 9 years of age and older. The company also completed Phase III trials for FMX103 for rosacea treatment and was developing FCD105 for acne.

Therapeutic areas: Women's HealthDermatologyOphthalmologyInfectious Diseases
Modalities: Topical foam formulationsTopical gel formulations
Industry: Biotech

Drug pipeline

1 asset

zilxi

Approved

Partnerships

LEO Pharma A/S (formerly Bayer HealthCare AG)Merz Pharmaceuticals, LLCAllergan plcDr. Reddy's

Beyond the preview

Go deeper on Foamix Pharmaceuticals Ltd..

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Foamix Pharmaceuticals Ltd..

Explore the full profile